Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

Fig. 1

CONSORT diagram. *Overall, 598 patients with molecular aberrations did not receive treatment in our program for the following reasons: preference to be treated elsewhere or declined Phase I treatment (n = 230, 38.5%), ineligibility (n = 177, 29.6%), treated after the cut-off date of the period of analysis (n = 62; 10.4%), worsening performance status (n = 57; 9.5%), received regional therapy (n = 31, 5.2%), lost to follow-up (n = 23, 3.8%), or insurance issues (n = 18; 3%)

Back to article page